List of Vaccines Companies in Taiwan - 6

Abnova is the first biotech company successfully integrated the IT-style management and industrial-scale antibody manufacturing. Our goal is to have at least one antibody to every human expressed gene in human genome. In Phase I of our business plans, we vastly expand the scope and availability of antibody reagents for the research market by taking a genome-wide approach to the high throughput production of human protein and antibody. There products are marketed through a combination of E-commerce based direct sales and a multi-tiered, sales network of over 49 distributors around the world. Starting from Year 2009 to 2013, in Phase II of the business plans, we have diversified into the systems arena focusing on antibody pairs, ELISA kits and instrumentation for rare cell isolation. In Phase III, we focus on in vitro diagnostics development concentrating on non-invasive, liquid biopsies of circulating tumor cells, ctDNA, and exosomes for precision medicine. Now in Phase IV (Year 2017 and later), we have focused on drug development specializing on immunotherapy. The value-added business has set the path of company's future growth and provided opportunity for Abnova to contribute to the biotech industry at large. We welcome researchers, biotech, and pharmaceutical companies to work with us and succeed together!

Adimmune Corp (4142) is a biotechnology company based out of Taichung City, Taiwan.

Genomics Bioscience and Technology Co., Ltd. is Taiwan's leading commercial genome sequencing company. Our diverse services encompass comprehensive gene sequencing technology and applications and oligonucleotide and peptide synthesis, meeting standards from RUO to GMP compliance. Committed to excellence, we collaborate with prestigious academic institutions and biotech companies to advance precise medical genetic testing and champion personalized precision medicine. With over 20 years of expertise and academic experience in the biotechnology field, we are equipped with state-of-the-art technology, including the Illumina Novaseq X Plus. We offer a comprehensive NGS workflow from sample preparation to bioinformatics analysis. Our dedicated goal is to support our partners in advancing Taiwan's biotechnology sector onto the international stage and highlighting the robust strength of Taiwan's biological sciences to the world. With Taiwan as our home base, we are set to make strides on the global stage.

Established in 2012, Medigen Vaccine Biologics Corp (MVC) is a subsidiary of Medigen Biotechnology Corp (www.medigen.com.tw), Taipei, Taiwan. MVC develops vaccines and biosimilars for important unmet medical needs. Our focus is to deliver affordable medicines for developing countries and with a particular focus on SE Asia. We aim to become one of the leading pharmaceutical companies for Taiwan and global communities. Humanity, innovation, and quality are MVC core values. We integrate biomedical technologies to improve human health so that every person, from infants to seniors, has a chance to be free from infectious diseases. Our most advanced products are MVC-1901 and MVC-EVA71. MVC-1901 is a spike-protein-based subunit vaccine for COVID-19. Based on a very large phase 2 trial powered to assess safety and efficacy by immunobridging, the vaccine has EUA status in Taiwan. Phase 3 trials for full approval are in progress. MVC-EVC71A is an inactivated whole virus-based vaccine for enteroviral disease in children between 2 months and 12 years of age. The vaccine has recently completed a phase 3 trial and is currently in regulatory review for commercial licensing.

OBI Pharma, Inc. is a Taiwan based bio-pharma company founded in 2002. Our mission is to improve health and the quality of life through innovative cancer therapeutics. We seek to develop and license novel therapeutic agents for unmet medical needs against cancer by targeting the Globo Series antigens (Globo H, SSEA-4), the AKR1C3 enzyme, and other promising targets. Our leading compound is Adagloxad simolenin, a late-stage novel active immuno-oncology (IO) Globo Series-based therapeutic vaccine for the treatment of epithelial cancers, such as breast, ovarian, lung, prostate, colon, gastric, and pancreatic cancer. OBI has a full spectrum of Globo Series IO pipeline, which includes both active (vaccine) and passive (monoclonal antibody & antibody drug conjugate) therapeutics. Development of OBI-888 (Globo H monoclonal antibody), OBI-833 (Globo Series vaccine) for epithelial cancers, OBI-999 (Globo H antibody drug conjugate), OBI-898 (SSEA-4 monoclonal antibody), and OBI-866 (SSEA-4 vaccine) for multiple cancers are also underway. In addition, development of OBI-3424, a novel First-in-Class compound targeting both solid and liquid that express the Aldo Keto Reductase 1C3 enzyme, further enriches the company’s pipeline profile. OBI Pharma, Inc. is publicly listed on the Taipei Exchange (TPEx: 4174); wholly-owned subsidiaries are present in the United States and China. The company is led by management team with a track record of success in new drug development and commercialization.

PapiVax Biotech, Inc. (PBI) is a biotechnology company that intends to become a global leader in immunotherapy for chronic viral infections and related cancers through application of our state-of-the-art immunology and virology expertise, first to develop safe and effective treatments for human papillomavirus (HPV) infections and related cancers and then to expand application of our immunotherapy platforms against other chronic virus infection-related human cancers.